Миноксидил — приговор или надежда?

Авторы:
  • А. Г. Гаджигороева
    ООО «Институт Красивых Волос», Москва, Россия, 105082
Журнал: Клиническая дерматология и венерология. 2016;15(4): 96-101
Просмотрено: 750 Скачано: 140
Миноксидил является базовым препаратом для наружной терапии андрогенетической алопеции у мужчин и женщин. Между тем отношение к миноксидилу неоднозначно как среди пациентов, так и среди врачей. Недостаточное понимание этиологии разных форм потери волос, отсутствие ясности в механизмах интеракции миноксидила с клетками-мишенями, в особенности с клетками волосяного фолликула, а также специфичность реакции самих волос на ранних этапах лечения компрометирует действие препарата на волосы и организм человека в целом, ограничивая терапевтические возможности при лечении облысения, снижает комплаентность лечению у пациента. В статье приводится обзор научных исследований о стимулирующих механизмах миноксидила на рост волос, о клинической эффективности и преимуществе использования лекарственной формы препарата в виде пены при андрогенетической алопеции.
Ключевые слова:
  • миноксидил
  • пена миноксидил
  • андрогенетическая алопеция
  • лечение

КАК ЦИТИРОВАТЬ:

Гаджигороева А.Г. Миноксидил — приговор или надежда?. Клиническая дерматология и венерология. 2016;15(4):96-101. https://doi.org/10.17116/klinderma201615496-101

Список литературы:

  1. Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfateinduced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther. 1988;245:751-760.
  2. Winquist RJ, Heaney LA, Wallace AA, et al. Glyburide blocks the relaxation response to BRL 34915 (cromakalin), minoxidil sulfate and diazoxide in vascular smooth muscle. J Pharmacol Exp Ther. 1989;248:149-156.
  3. Yost CS. Potassium channels. Basic aspects, functional roles and medical significance. Anesthesiol. 1999;90:1186-1203.
  4. Yokoshiki H, Sunagawa M, Seki T, et al. ATP-sensitive K+ channels in pancreatic, cardiac and vascular smooth muscle cells. Am J Physiol. 1998;274:C25-C37.
  5. Schwanstecher M, Sieverding C, Dorschner H, et al. Potassium chanel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J. 1998;17:5529-5535.
  6. Li M, Marubayashi A, Nakaya Y, et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001;117:1594-6000.
  7. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
  8. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409-417.
  9. Goldman CK, Tsai JC, Soroceanu L, et al. Loss of vascular endothelial growth factor in human alopecia hair follicles. J Invest Dermatol. 1995;104:18-20.
  10. Kozlowska R, Blume-Peytavi U, Kodelja V. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res. 1998;290:661-668.
  11. Lachgar S, Charveron M, Gall Y, et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138:407-411.
  12. Johnson GA, Barsuhn KJ, McCall JM. Sulfation of minoxidil by liver sulfotransferase. Biochem Pharmacol. 1982;31:2949-2954.
  13. Falany CN, Kerl EA. Sulfation of minoxidil by human liver phenol sulfotransferase. Biochem Pharmacol. 1990;40:1027-1032.
  14. Johnson GA, Baker CA. Sulfation of minoxidil by human platelet sulfotransferase. Clin Chim Acta. 1987;169:217-227.
  15. Johnson GA, Baker CA, Knight KA. Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. J Invest Dermatol. 1992;98:730-733.
  16. Buhl AE, Waldon DJ, Baker CA, et al. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol 1990;95:553-557.
  17. Dooley TP, Walker CJ, Hirshey SJ, et al. Localization of minoxidil sulfotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles. J Invest Dermatol. 1991;96:65-70.
  18. Hamamoto T, Mori Y. Sulfation of minoxidil in keratinocytes and hair follicles. Res Commun Chem Pathol Pharmacol. 1989;66:33-44.
  19. Baker CA, Uno H, Johnson GA. Minoxidil sulfation in the hair follicle. Skin Pharmacol 1994;7:335-339.
  20. Dooley TP. Molecular biology of the human cytosolic sulferotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp Dermatol. 1999;8:328-329.
  21. Dooley TP. Molecular biology of the human cytosolic sulferotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp Dermatol. 1999;8:328-329.
  22. Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553-577.
  23. Baker CA, Uno H, Johnson GA. Minoxidil sulfation in the hair follicle. Skin Pharmacol. 1994;7(6):335-339.
  24. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1-3):53-67.
  25. Buhl AE, Baker CA, Dietz AJ, et al. Minoxidil sulfotransferase activity influence the efficacy of Rogaine topical solution (TS): enzyme studies using scalp and platelets. J Invest Dermatol. 1994;102:534.
  26. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109:53-67.
  27. Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014 May-Jun;27(3):171-173.
  28. Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia Dermatologic Therapy. 2014;27:252-254.
  29. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trüeb R, Rzany B, Blume-Peytavi U; European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011 Oct;9:Suppl 6:S1-S57.
  30. Franz TJ. Percutaneous absorption of minoxidil in men. Arch Dermatol. 1985 Feb;121(2):203-206.
  31. Mahe YF, Michelet JF, Billoni N, Jarousse F, Buan B, Commo S, Seint-Leger D, Bernard BA. Androgenetic alopecia and microinflammation. Int J Dermatol. 2000;39:576-584.
  32. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477.
  33. Warshaw EM, Botto NC, Maibach HI, Fowler JF Jr, Rietschel RL, Zug KA, et al. Positive patch-test reactions to propylene glycol: a retrospective cross-sectional analysis from the North American Contact Dermatitis Group, 1996 to 2006. Dermatitis. 2009;20:14-20.
  34. Lessmann H, Schnuch A, Geier J, Uter W. Skin-sensitizing and irritant properties of propylene glycol. Contact Dermatitis. 2005;53:247-259.
  35. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, doubleblind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-774.
  36. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47:377-385.
  37. Ulrike Blume-Peytavi, Kathrin Hillmann, Ekkehart Dietz, Douglas Canfield, and Natalie Garcia Bartels. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011 Dec;65(6):1126-1134.
  38. van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2012;(5):CD007628.
  39. DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol. 1994;130(3):303-307.
  40. Jacobs JP, Szpunar CA,Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol. 1993;32(10):758-762.
  41. Olsen EA. Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis. 1991;48(3):243-248.
  42. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-553. doi: 10.17116/klinderma201615496-101